Clinical Trials Logo

Glutamine clinical trials

View clinical trials related to Glutamine.

Filter by:
  • None
  • Page 1

NCT ID: NCT05406882 Recruiting - Gut Microbiota Clinical Trials

The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis

Start date: April 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Radiation proctitis is a common complication after radiation therapy for pelvic tumors. The investigators found that live bifidobacterium and lactobacillus tablets combined with compound glutamine enteric-coated capsules can significantly relieve the symptoms of radiation proctitis through preliminary clinical practice, but the mechanism is unknown. Through a prospective randomized controlled study, this study intends to investigate the incidence of grade 2 or higher acute radiation proctitis in patients of locally advanced rectal cancer after radiotherapy with the combined therapy. And through various scales, next-generation sequencing methods and other methods to evaluate the clinical symptoms, colonoscopy, imaging, and changes in the species and abundance of intestinal flora before and after treatment. To further explore the related pathways and mechanisms affecting radiation proctitis.

NCT ID: NCT04353869 Recruiting - Clinical trials for Cardiovascular Complications

Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications

GLUTADIAB
Start date: November 16, 2020
Phase:
Study type: Observational

Experimental data suggest that glutamine catabolism in involved in the activation of macrophages by generating TCA(Tricarboxylic acid) intermediates that promote the pro-inflammatory polarization of macrophages. The project investigates the possible link between glutaminolysis, monocytes polarization and diabetes related cardiovascular complications in humans

NCT ID: NCT02738762 Withdrawn - Clinical trials for Mechanical Ventilation

Glutamine Supplementation

Start date: November 15, 2017
Phase: N/A
Study type: Interventional

Earlier studies showed a benefit in survival when glutamine was given intravenously and these studies lead to recommendations that glutamine should be given to critically ill patients. The ESPEN guidelines recommend 0,2-0,4 g/kg/d intravenous glutamine added to standard parenteral nutrition . Until recently it was not possible to obtain a plasma glutamine level fast enough to consider the result for clinical decision making. With the availability of a Point of Care (POCT) measurement of plasma glutamine level a measurement can be performed short after the collection of blood. This offers the possibility to identify a patient with a low plasma glutamine level shortly after admission and use repeated measurements for evaluation of the response to supplementation of glutamine.